both prescribed and over-the-counter (OTC) medication during pregnancy is caused by the absence of randomized clinical trials. Therefore, information is obtained through observational studies, case reports, and animal studies, all with limitations that make it difficult to establish a relationship between fetal drug exposure and adverse effects (Illamola et al., 2018) .
Contrary to the use of medication in pregnancy, medication use during lactation seems to have received much less attention. There may be less concern about toxicity from medication in mother's milk because possible adverse consequences often are evident, temporal, and less serious. Although the benefits of breastfeeding probably will outweigh the potential negative effects of medication ingested through mother's milk, in the majority of cases, there are examples of medicines that, when used during lactation, clearly have harmful effects on the infant (e.g., opioids, such as oxycodone and codeine, and central nervous system depressants, such as midazolam, clonazepam, and diazepam; Anderson, Manoguerra, & Valdes, 2016) . Counseling women on medication use during lactation is thus complex (Jayawickrama, Amir, & Pirotta, 2010) .
The aim of the current study was to determine (a) the prevalence of medication use (including OTC and homeopathic medicines) during (high-risk) pregnancy and lactation, (b) the types and safety of these medicines, and (c) the influence of medication use on the decision to initiate breastfeeding. With this information at hand, it will be possible to make recommendations about future pharmacokinetic studies on the most commonly used medications.
Methods

Design
We conducted a cross-sectional survey study with two phases (prenatal and during lactation). This design was the most appropriate one to answer our research question given that cross-sectional designs are generally used for populationbased surveys to assess the prevalence of outcomes or exposures. The study was approved by the VU University Medical Center (VUmc) ethics committee.
Setting
The study took place at VUmc, a tertiary center in Amsterdam, the Netherlands. Patients were enrolled between September 2012 and February 2013. In the Netherlands, it is mandatory for everyone to have at least basic health insurance. Most medical costs made during pregnancy are covered by this insurance. Prenatal care is provided by midwives, unless there is a medical indication for obstetrician-led care. Women without a medical indication can opt for a homebirth or a polyclinical birth in hospital (midwife led), such as VUmc. Because VUmc is a tertiary center, complicated deliveries take place in this center. All women in the Netherlands are entitled to a total of 16 weeks of paid pregnancy and maternity leave. Ten weeks of the leave must be taken after the birth. Approximately 80% of women initiate breastfeeding and 39% of newborns are exclusively breastfed at 6 months of age (Peeters, Lanting, & van Wouwe, 2015) . Since 2014, VUmc has the Baby-Friendly designation.
Sample
All pregnant women giving birth at the obstetrics ward of VUmc and all pregnant women under primary midwife-led care at three midwifery offices connected to VUmc were eligible for participation. Women were excluded if their newborn had a life expectancy of less than 72 hr or if they did not speak Dutch, English, or French. During the study period, 440 women who delivered their newborn infant in VUmc were eligible for the study, 172 of which were not included (see Figure 1 ). Another 5 participants delivered without the supervision of an obstetrician and were therefore considered to have a low-risk delivery. In addition, 50 women under primary midwife-led care gave their consent to be approached for the interview by phone. Eventually, 26 of them could not be included (see Figure 1) . Therefore, data about medication use during pregnancy were obtained for 263 participants with a medical (high-risk) delivery and 29 participants with a home or short-stay hospital (low-risk) delivery.
Two hundred fifty-nine (88.7%) of all pregnant participants intended to breastfeed their newborns. Eventually, 258 participants actually did: 231 of 263 participants (87.8%) with a high-risk delivery and 27 of 29 participants (93.3%) with a low-risk delivery. We did not send a questionnaire to 8 participants whose infant died >72 hr after birth or was still admitted with a poor prognosis. One hundred seventeen participants did not return the questionnaire. Therefore, data about medication usage during lactation, the second phase of (Charan & Biswas, 2013) , the calculated minimal number of participants to include was 196.
Key Messages
Data Collection
Informed consent was obtained for all participants. Data were obtained from the participants' medical chart and by means of a structured interview conducted by a trained medical student with an author-developed questionnaire, lasting approximately 10 min. Data about the pregnancy period were obtained within the first 15 days after delivery for high-risk participants (n = 263) and within 5 weeks after delivery for low-risk participants (n = 29), by means of the structured interview using the questionnaire.
Within 4 months after delivery and discharge home, a corresponding, second questionnaire, to obtain data about medication usage during lactation, was sent to all participants.
Measurement
The first questionnaire comprised questions about demographic data (i.e., maternal age and education level and ethnicity of both parents) and obstetric data (i.e., parity, reason for high-risk delivery, gestational age [GA] , mode of delivery, birth weight, and infant gender) and relevant medical information (e.g., chronic disease diagnosis). Data were first obtained from the participants' medical chart and verified and completed during the interview to maximize data accuracy. Furthermore, all medication used during any part of the pregnancy, including medication for acute/short-term illness, medication for chronic/long-term diseases, OTC and homeopathic medication (including herbs; National Center for Complementary and Integrative Health, 2015) , and probiotics (including probiotic supplements and probiotic dairy product preparations) was obtained from the medical chart and completed during the interview. Finally, thoughts on initiation of breastfeeding were verified. Recall was aided by giving an extensive number of possible indications for which medication could have been used. Participants who used only vitamin D, folic acid, and/or multivitamins (without fish oil) during pregnancy were classified as nonmedication users because obstetricians, midwives, and general practitioners recommend these products to all pregnant women in the Netherlands. In addition, labor-inducing medication and analgesics and antibiotics administered during labor were excluded.
The questionnaire was first used in a pilot study from October 2011 to January 2012. During these 4 months, data about medication use by participants delivering at VUmc were extracted from their medical charts (n = 62). Afterward, participants were interviewed using the questionnaire and their reported medication use was compared with medication use noted in the participants' medical charts. For all participants, medication extracted from the medical chart also was reported during the interview. In addition, it appeared that 15 (24.2%) medical charts missed some medication that participants did mention during the interview. The pilot study elicited no changes to the questionnaire (see Supplemental File 1). Data from the pilot study were not included in the current study.
For the current study, a corresponding, second questionnaire (with cover letter and reply-paid envelope) was sent to all participants within 4 months after delivery and discharge home (see Supplemental File 2). This second questionnaire included a list of all possible medicines and was already filled out with information on medication use during pregnancy obtained during the interview. Participants were asked to complement the list with medications used during the period in which they were breastfeeding, up to the present. Breastfeeding was defined by any means of providing the infant with mother's own milk (exclusive or partial breastfeeding, feeding pumped milk, and with or without complementary feeding).
All prescribed and OTC medicines were classified according to the Anatomical Therapeutic Chemical classification system of the World Health Organization (2011). Safety of prescribed and OTC medicines was classified according to the risk classification system from the Teratological Information Service (Lareb, 2014) . This system is consulted frequently by Dutch physicians and is available online and by phone. The service is run by an independent institute (Lareb) funded by the Ministry of Health, Welfare and Sports, which monitors the safety of medicines and vaccines in the Netherlands. Lareb works closely with similar organizations in more than 100 countries worldwide and has officially been appointed as the WHO Collaborating Centre for Pharmacovigilance in Education and Patient Reporting. They advise on medication use during pregnancy or lactation. For pregnancy, medicines are grouped into six classes and for lactation into five (see Table 1 ).
Data Analysis
All analyses were performed using SPSS Version 22.0 (IBM Corporation, 2013). Descriptive statistics were used to summarize participants' demographic characteristics. For Study Aim 1, the description of the prevalence of medication use, values were expressed as mean (SD), median (range), or percentage. Differences in prevalence of medication use between participants delivering in the hospital because of a medical reason (high-risk participants) and participants delivering under primary midwife-led care by a midwife connected to VUmc (low-risk participants) were tested using chi-square or Fisher exact test; p values of < .05 were considered statistically significant. For Study Aim 2, the description of types and safety of medicines, and for Study Aim 3, the influence of medication use on the decision to initiate breastfeeding, we did frequency distributions (percentages).
Results
Characteristics of the Sample
Mean (SD) age of participants with a high-risk delivery and a low-risk delivery was 33.2 (5.2) and 32.0 (4.0) years, respectively. Infants born after a high-risk delivery had a mean GA of 38.1 (3.6) weeks and a mean birth weight of 3,092 (902.6) g, and 148 (53.2%) were male, whereas infants born after a low-risk delivery had a mean GA of 40.2 (1.0) weeks and a mean birth weight of 3,591 (438.1) g, and 18 (62.1%) were male. Additional demographic and obstetric characteristics and causes for high-risk delivery are shown in Table 2 .
Study Aim 1: Prevalence of Medication Use
Of all included participants, 279 (95.5%) reported on the use of prescribed, OTC, or homeopathic medication during pregnancy. Prescribed medication was used by 199 participants (68.2%), whereas 272 participants (93.2%) and 105 participants (36.0%) used OTC and homeopathic medicines, respectively. Excluding homeopathic medicines did not change the prevalence of 95.5%. Significantly more medication was used by participants with a high-risk delivery (254, 96.6%) compared with participants with a low-risk delivery A majority of the lactating participants used some sort of medication during lactation (112/133, 84.2%). Prescribed medications were used by 51.1% of participants, and OTC and homeopathic medicines by 75.9% and 29.3% of participants, respectively. Excluding homeopathic medicines diminished the prevalence of medication use of 84.2% by 2.2%. Participants used a median (range) of 3.0 (0-11) different medicines per person during lactation and 2.0 if homeopathic medication was excluded.
Study Aim 2: Types and Safety of Medication
In both groups of pregnant participants, the most frequently used types of medication included non-opioid analgesics, This class also includes medication with the potential to diminish the milk production but without known risks to the infant. For this study, medicines with this potential were considered safe (equal to Class 1).
antacids, and vitamins (other than vitamin D). Additionally, antibiotics and laxatives were among the most actively used medicines in high-risk participants, whereas probiotics were the most actively used in low-risk participants (see Figure 2 ). In the lactating participants, again, non-opioid analgesics and vitamins were the most frequently used medicines, followed by iron supplements, laxatives, and probiotics (see Figure 3) .
The prevalence of the use of medicines that were not classified as (probably) safe by the risk classification system is shown in Table 3 . All 19 pregnant participants (6.5%) who used at least one type of medication classified as teratogenic (Classes 4 and 5) belonged to the high-risk delivery group and all medicines were by prescription. In 16 participants, it concerned Class 5 medicines, including acenocoumarol, Proluton/ progesterone, methotrexate, paclitaxel, cyclophosphamide, and Adriamycin, whereas the remaining 3 participants used Class 4 medicines, including carbamazepine and valproic acid. One of the 19 participants was diagnosed with an intrauterine fetal death at 22 weeks GA (part of twins) and 7 gave birth prematurely (two sets of twins)-1 of which died of necrotizing enterocolitis whereas another infant was born with dysmorphic features including polydactyly and hypertelorism. The remaining 12 infants were all healthy term born.
Medication with a known or suspected pharmacological effect (Classes 2 and 3 combined) was taken by 86 different participants (29.5%). In 82 participants, these medicines were by prescription, whereas OTC medication and both types of medicines were used in 2 and 2 participants, respectively. In 19 of the 86 participants (22.1%), medication was prescribed deliberately because of its effect on the unborn child (e.g., glucocorticoids to accelerate lung maturation).
Probiotics and fish oil, used by 22.9% and 41.1% of participants, respectively, are not included in the Teratological Information Service classification.
During lactation, 15 participants (11.3%) used paracetamol + codeine or morphine, which pose a (possible) risk to the infant Hypertension includes preexistent or pregnancy-induced hypertension; preeclampsia; and hemolysis, elevated liver enzymes, and low platelets.
f Other reasons include conceived by in vitro fertilization, meconium-stained amniotic fluid, breech position infant, and placenta previa.
(Class 4). All remaining medicines used by the breastfeeding participants are classified as safe or probably safe (Classes 1 and 2; see Table 1) , with a comment on dose or duration for five medicines (used by 5 participants, 4.5%) and advice to observe the infant for side effects for two other medicines (used by 4 participants, 3.6%). 
Study Aim 3: Influence of Medication Use on Initiation of Breastfeeding
The decision not to initiate lactation was reported to be due to medication in 13 of 34 participants (38.2%). In 10 of these 13 participants (76.9%), this decision was based on the use of medicines classified as risk unknown (Class 3: hydroxychloroquine, melatonin, ondansetron, and pregabalin) or posing a possible risk (Class 4: fluoxetine, morphine, methotrexate, sotalol, tamoxifen, and zonisamide). In 1 participant (7.7%), there was agreement with the classification system that the medicine (lamotrigine) could affect the infant, but monitoring the infant could be an option according to the system. The remaining 2 participants did not use medication (adalimumab, hydrocortisone (systemic)/infliximab) that would be expected to cause a problem for the infant (Class 2). All but 1 of the 13 participants consulted a physician (either an obstetrician or the medical specialist involved in the treatment of their chronic illness). The remaining participant received advice from a midwife and a lactation consultant.
Of all lactating participants (n = 133), 22 participants (16.5%) clearly indicated that their medication use made them take preventive actions during lactation: 5 participants stopped medication during breastfeeding, 4 temporarily fed their infants with formula because of the use of medication, 2 participants stopped lactation because of the need to start taking medication, 10 asked for more information and changed to compatible medicines if necessary, and 1 participant observed her infant for possible side effects of the medicine she used. Six of the 11 participants (54.5%) who temporarily fed their infant with formula, who stopped lactation, or who stopped the use of medication used medicines classified as posing a possible risk (Class 4, including estradiol, escitalopram, and morphine), posing a risk (Class 5, including clemastine), or risk unknown (Class 3, including ciprofloxacin and ketanserin).
Discussion
The overall medication use among a Dutch cohort of (highrisk) pregnant and breastfeeding participants was very high.
There was a significant difference between high-risk and low-risk pregnant participants regarding prevalence of medication use. Nevertheless, in low-risk participants, the prevalence of medication use during pregnancy was also high. Our prevalence of medication use during pregnancy is in line with results from other, relatively recently performed studies, despite our large number of high-risk pregnant participants (Lupattelli et al., 2014; Mitchell et al., 2011; Schirm, Meijer, et al., 2004) . However, these researchers did not take into account homeopathic medication. When we excluded homeopathic medicines, it did not (substantially) change the prevalence during pregnancy and lactation, implying that most participants who used homeopathic medicines also used medicines by prescription (either simultaneously or at different times during the pregnancy and lactation periods).
Recent studies with a focus on medication use during lactation are more limited. A review by Saha, Ryan, and Amir (2015) on medication use by postpartum women included 18 studies conducted between 1982 and 2007. Ten of the reviewed studies had (limited) information about different types of medicines used during lactation, and use of prescription and nonprescription medication was not differentiated in the included studies. Our prevalence was in line with their results. In a Dutch survey performed a decade ago, researchers reported the prevalence of use of prescribed, OTC, and homeopathic medicines as 65.9% (Schirm, Schwagermann, Tobi, & de Jong-van den Berg, 2004) . Clearly, this prevalence has increased considerably over the years. This might be explained by the older age at which women become pregnant nowadays, with a higher prevalence of preexisting medical comorbidities for which medication is needed and an increased risk of obstetric complications that require pharmacotherapy (Ayad & Costantine, 2015) .
The high prevalence of medication use by breastfeeding participants also has implications for donor milk banks and for informal milk sharing, which is becoming more prevalent; all of our participants were potential donors. Donor milk is increasingly used, with more than 200 milk banks in Europe and a lively trade on the Internet (Arslanoglu, Ziegler, & Moro, 2013 ; European Milk Bank Association (Lareb, 2014) .
[http://www.europeanmilkbanking.com]). Recipients of donor milk are in general preterm infants; feeding them with donor milk could potentially lead to the ingestion of small amounts of a considerable number of medicines, because they often receive milk from multiple donors besides their own mother's milk. Apart from the potential risk of the medicines, this situation could eventually lead to medication interaction, especially because most preterm infants also receive medication as part of their treatment in the neonatal intensive care unit. Moreover, the danger of drug accumulation exists because of not-yet-fully-developed liver and kidney function, and infants might be prone to central side effects because of the increased permeability of the bloodbrain barrier (Ku & Smith, 2015) . Donor milk banks, including the one in the Netherlands, therefore often decide to exclude all women on medication; European milk banks do not routinely screen donor milk for the presence of medication. Determining the risk of medication more precisely would enable more women to donate their mother's milk. Our participants used multiple different medicines per person, both during pregnancy and during lactation. The most frequently used medication during (high-risk and low-risk) pregnancy and lactation reported in the current study was in great accordance with earlier European studies (Saha et al., 2015; Schirm, Meijer, et al., 2004; Schirm, Schwagermann, et al., 2004) , including Passmore et al. (1984) , who concluded that safety data about analgesics, anti-emetics, and some antimicrobials (as well as hypnotics and antihistamines) were urgently needed. Now, 30 years later, that conclusion seems still relevant. Probiotics were not mentioned in previous studies, possibly because their usage was rare at the time these studies were conducted. Moreover, until now, most probiotics have been registered as food supplements, not as medication; therefore, they did not have to fulfill the legal and/or efficacy criteria. Recently, Gilmartin, Vo-Tran, and Leung (2018) concluded that the available safety data of probiotics can be considered neither alarming nor having the robustness to suggest an absolute recommendation as safe during pregnancy. Safety depends on the strains within the products used, usually being one or more varieties of bifidobacterium, lactobacillus, saccharomyces, and streptococcus thermophiles. Especially for the latter two strains, no safety evidence is available (Gilmartin et al., 2018) .
In the Netherlands, the online available risk classification system from the Teratological Information Service (Lareb, 2014) is generally consulted for advice on safety when prescribing medication or counseling pregnant and lactating women. The service is equivalent to authoritative sources consulted in other countries, such as Lactmed (2018) and the InfantRiskCenter (https://www.infantrisk.com/). This system classifies medicines according to current evidence and reported side effects. Unfortunately, for a majority of medicines, the evidence is too scarce to give (clear) advice according to the service. This emphasizes the difficulties physicians are facing. In our study, pregnant women not seldom used at least one medicine for which the risk for the embryo, fetus, or newborn infant was unknown. On the contrary, none of the breastfeeding participants used medication with an unknown risk, but some participants did not start breastfeeding because of medicines with an unknown risk. As previously described, fear of harming the infant often leads to the decision or advice to stop breastfeeding or discontinue the use of medication (Hussainy & Dermele, 2011) . However, the fact that medication poses some risk to the infant does not always mean that it is incompatible with breastfeeding. In many cases, it might be possible to address these risks through appropriate monitoring of the infant. Antidepressants, for example, are often a reason to discourage women from breastfeeding because they have an intermediate to long halflife and are excreted in human milk. However, not all antidepressants are always found in the infants' serum, and some of the medicines belonging to this group can be used during breastfeeding if the infant is closely monitored for drowsiness and adequate weight gain (Davanzo, Copertino, De Cunto, Minen, & Amaddeo, 2011) .
A substantial number of participants in this study used homeopathic medications (including herbs), which are not included in the classification system. In general, little is known about their safety. Given that homeopathic medicines sometimes contain pharmacologically active ingredients, caution is needed when it comes to the use of these remedies during pregnancy and lactation (Dante, Bellei, Neri, & Facchinetti, 2014; Gilmartin et al., 2018) .
Limitations
This study holds some limitations. Retrospective questioning is prone to cause recall bias. By interviewing the participants and using indication-oriented questions, however, we attempted to diminish this error (Mitchell, Cottler, & Shapiro, 1986) . Another limitation is that no questions about the frequency of medication use or the dosage were asked. Also, we did not ask during what pregnancy trimester(s) medication was used. These parameters did not fall within the scope of our study but are of importance for determining the safety of medicines more precisely. The same applies for our broad definition of breastfeeding, because maternal medication use might have a greater safety impact on exclusively breastfed infants than on infants who are partly fed with formula. Furthermore, the sample size of the low-risk group was underpowered and the difference in numbers of participants between the high-risk and low-risk groups might have caused selection bias. The same could be true for our results on lactation. Baseline characteristics from the respondents did, however, not differ from those of the total group. Finally, the questionnaires were sent to participants within 4 months after delivery but at various time points; therefore, some participants had already stopped breastfeeding, whereas others had not. This might have resulted in an underestimation of the prevalence of medication use during lactation.
Conclusion
The prevalence of overall medication use is high in pregnant and lactating women in the Netherlands. For a majority of medicines, there is still not enough evidence on safety during pregnancy and lactation. Therefore, there is a need for pharmacokinetic and pharmacodynamic studies of these medicines, especially of the most frequently used medications. Furthermore, considering the difficulty of conducting studies during pregnancy and, in part, during lactation, pharmacovigilance and phytosurveillance reporting systems are of importance for postmarketing research in this field. In addition, awareness of the possible risks and interactions of medications taken during pregnancy should be optimized, because use of medication with a suspected pharmacological effect is still common.
